Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Role of PD‐1 in modulating IFN‐γ‐CXCL9/10‐CXCR3 signaling in breast cancer

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

PD-1 regulation in immune homeostasis and immunotherapy

Optimization of Cancer Immunotherapy on the Basis of Programmed Death Ligand‐1 Distribution and Function

Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function

The Anticancer Immune Response of Anti-Pd-1/pd-l1 and the Genetic Determinants of Response to Anti-Pd-1/pd-l1 Antibodies in Cancer Patients

Role of CXCR3 Signaling in Response to Anti-Pd-1 Therapy.

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

IFI30 as a key regulator of PDL1 immunotherapy prognosis in breast cancer

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Sarcoidosis presenting as massive splenomegaly and bicytopenia

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

The role of PD-1 signaling in health and immune-related diseases

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

PD-1/PD-L1 Counterattack Alliance: Multiple Strategies for Treating Triple-Negative Breast Cancer